Mortality, patient-reported outcome measures, and the health economic burden of prosthetic joint infection
Prosthetic joint infection (PJI) is one of the most devastating complications for a patient following arthroplasty. This scoping review aims to evaluate the burden of PJI on individual patients and the healthcare system regarding the mortality rate, patient-reported quality of life, and healthcare resource utilisation. Patients with PJI have up to a five-fold higher mortality rate than those who have undergone an uninfected primary arthroplasty. There is an increased use of ambulatory aids and reduced joint function scores in patients with PJI. Global quality of life is poorer, specifically measured by the EQ-5D. Direct hospitalisation costs are two- to five-fold higher, attributed to surgery and prostheses, antibiotics, and a prolonged inpatient stay. There is an immense clinical and health economic burden secondary to PJI worldwide. This is expected to rise exponentially due to the increasing number of primary procedures and an ageing population with comorbidities Improving preventative and treatment strategies is imperative for patients and the healthcare system.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
EFORT open reviews - 8(2023), 9 vom: 01. Sept., Seite 690-697 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Xu, Yangqi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Arthroplasty |
|---|
| Anmerkungen: |
Date Revised 03.11.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1530/EOR-23-0078 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361536186 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361536186 | ||
| 003 | DE-627 | ||
| 005 | 20231226085341.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1530/EOR-23-0078 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1205.xml |
| 035 | |a (DE-627)NLM361536186 | ||
| 035 | |a (NLM)37655835 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Xu, Yangqi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Mortality, patient-reported outcome measures, and the health economic burden of prosthetic joint infection |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 03.11.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Prosthetic joint infection (PJI) is one of the most devastating complications for a patient following arthroplasty. This scoping review aims to evaluate the burden of PJI on individual patients and the healthcare system regarding the mortality rate, patient-reported quality of life, and healthcare resource utilisation. Patients with PJI have up to a five-fold higher mortality rate than those who have undergone an uninfected primary arthroplasty. There is an increased use of ambulatory aids and reduced joint function scores in patients with PJI. Global quality of life is poorer, specifically measured by the EQ-5D. Direct hospitalisation costs are two- to five-fold higher, attributed to surgery and prostheses, antibiotics, and a prolonged inpatient stay. There is an immense clinical and health economic burden secondary to PJI worldwide. This is expected to rise exponentially due to the increasing number of primary procedures and an ageing population with comorbidities Improving preventative and treatment strategies is imperative for patients and the healthcare system | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a arthroplasty | |
| 650 | 4 | |a health economic | |
| 650 | 4 | |a patient-reported outcome measure | |
| 650 | 4 | |a prosthetic joint infection | |
| 700 | 1 | |a Huang, Tony B |e verfasserin |4 aut | |
| 700 | 1 | |a Schuetz, Michael A |e verfasserin |4 aut | |
| 700 | 1 | |a Choong, Peter F M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t EFORT open reviews |d 2016 |g 8(2023), 9 vom: 01. Sept., Seite 690-697 |w (DE-627)NLM271476672 |x 2058-5241 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2023 |g number:9 |g day:01 |g month:09 |g pages:690-697 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1530/EOR-23-0078 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2023 |e 9 |b 01 |c 09 |h 690-697 | ||